Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence
OTTAWA, ON / ACCESSWIRE / January 29, 2021 /
Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company s Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF
TM Reborn1
TM clinical trial in cancer patients with breakthrough pain. This is really good news for all of us and in particular for the cancer patients that suffer from breakthrough pain. We aim to initiate this proof-of-concept trial designed to demonstrate that QIXLEEF
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U S Reborn1(TM) Clinical Trial to Commence theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.